Kanagawa, Japan

Takayoshi Ido



 

Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 48(Granted Patents)


Location History:

  • Kamakura, JP (2016 - 2018)
  • Kanagawa, JP (2015 - 2024)

Company Filing History:


Years Active: 2015-2024

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Takayoshi Ido

Introduction

Takayoshi Ido is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. With a total of 13 patents to his name, Ido's work is recognized for its potential impact on medical science.

Latest Patents

Ido's latest patents focus on pharmaceutical compositions for the treatment and prevention of cancer. One notable patent describes an antibody or a fragment thereof that has immunoreactivity to a polypeptide comprising not less than 7 continuous amino acids in the CD179b protein. This protein has been identified as a cancer antigen specifically expressed on the surfaces of cancer cells. The implications of this work are profound, as it can be utilized for therapy and/or prophylaxis of cancer.

Career Highlights

Throughout his career, Takayoshi Ido has been associated with Toray Industries, Inc., where he has been able to leverage his expertise in developing innovative solutions for healthcare challenges. His dedication to research and development has positioned him as a key figure in the pharmaceutical industry.

Collaborations

Ido has collaborated with notable colleagues, including Fumiyoshi Okano and Takanori Saito. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

In summary, Takayoshi Ido's contributions to cancer treatment through his innovative patents highlight his role as a leading inventor in the pharmaceutical field. His work continues to inspire advancements in medical science and offers hope for improved cancer therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…